Levodopa-Carbidopa Intestinal Gel (LCIG)

DRUG3 trials

Sponsors

AbbVie (prior sponsor, Abbott), AbbVie

Conditions

Advanced Idiopathic Parkinson's DiseaseAdvanced Parkinson's DiseaseParkinson's Disease (PD)

Phase 3

Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease

CompletedNCT00660673

AbbVieAdvanced Parkinson's Disease

Start: 2009-11-13End: 2021-11-30Updated: 2022-12-02

A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)

CompletedNCT02799381

AbbVieParkinson's Disease (PD)

Start: 2017-02-09End: 2019-09-19Updated: 2020-08-18

Phase 4

Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact

CompletedNCT00141518

AbbVie (prior sponsor, Abbott)Advanced Idiopathic Parkinson's Disease

Start: 2006-03-31End: 2011-04-30Updated: 2016-07-18

Related Papers

Dyskinesia and Pain in Advanced Parkinson's Disease: Post Hoc Analysis from the Phase 3b, Open-Label, Randomized DYSCOVER Study.

2024-02-122 citations

2611 Dyskinesia signs and symptoms, and quality of life in Parkinson’s Disease: post hoc analysis from the DYSCOVER study

2023-08-01

Levodopa‐Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial

Movement Disorders2021-07-0857 citations

Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease.

2018-03-2362 citations